IGFBP2 and type 2 diabetes mellitus: Our PheWAS indicated that 16p11.2 BP2–3 deletion carriers were at significantly increased risk for T2D (odds ratio [OR] = 7.2; p = 1.0 × 10−11) with considerably earlier onset of disease (hazards ratio [HR] = 6.1; pCox-PH = 8.4 × 10−16) and were more likely to receive insulin treatment (OR = 8.4; p = 6.9 × 10−6).